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Indole-3-carbinol (I3C) and genistein are naturally occurring chemicals derived from cruciferous vegetables and soy, respectively, with
potential cancer prevention activity for hormone-responsive tumours (e.g., breast and prostate cancers). Previously, we showed that
I3C induces BRCA1 expression and that both I3C and BRCA1 inhibit oestrogen (E2)-stimulated oestrogen receptor (ER-a) activity in
human breast cancer cells. We now report that both I3C and genistein induce the expression of both breast cancer susceptibility
genes (BRCA1 and BRCA2) in breast (MCF-7 and T47D) and prostate (DU-145 and LNCaP) cancer cell types, in a time- and dose-
dependent fashion. Induction of the BRCA genes occurred at low doses of I3C (20mM) and genistein (0.5–1.0mM), suggesting
potential relevance to cancer prevention. A combination of I3C and genistein gave greater than expected induction of BRCA
expression. Studies using small interfering RNAs (siRNAs) and BRCA expression vectors suggest that the phytochemical induction of
BRCA2 is due, in part, to BRCA1. Functional studies suggest that I3C-mediated cytoxicity is, in part, dependent upon BRCA1 and
BRCA2. Inhibition of E2-stimulated ER-a activity by I3C and genistein was dependent upon BRCA1; and inhibition of ligand-inducible
androgen receptor (AR) activity by I3C and genistein was partially reversed by BRCA1-siRNA. Finally, we provide evidence suggesting
that the phytochemical induction of BRCA1 expression is due, in part, to endoplasmic reticulum stress response signalling. These
findings suggest that the BRCA genes are molecular targets for some of the activities of I3C and genistein.
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Indole-3-carbinol (I3C) is a phytochemical found in cruciferous
vegetables, such as cabbage and cauliflower. Epidemiologic studies
suggest a correlation between a diet high in such vegetables and
reduced breast cancer rate (Graham et al, 1982). In animal studies,
a diet high in these vegetables inhibited chemical carcinogen-
induced tumours; and dietary supplementation with I3C could
prevent oestrogen-dependent tumours (breast, cervical, endome-
trial cancers) (Bradlow et al, 1991; Kojima et al, 1994; Jin et al,
1999). In clinical studies, I3C caused regression of cervical
intraepithelial neoplasia (Bell et al, 2000) and regression or a
decreased growth rate of recurrent laryngeal polyps (Rosen et al,
1998). Indole-3-carbinol anticancer activity is attributed, in part, to
its anti-oestrogenic activity: it stimulates 2-hydroxylation and
inhibits 16a-hydroxylation of oestrone, leading to inactive
oestrone metabolites (Michnovicz and Bradlow, 1990). Indole-3-
carbinol may also interact directly with the oestrogen receptor
(ER-a) and inhibit its activity (Jin et al, 1999); and it cooperates
with Tamoxifen to inhibit breast cancer cell proliferation (Cover
et al, 1999).
Indole-3-carbinol also exerts oestrogen-independent actions. It
can inhibit cell cycle progression, induce apoptosis, and inhibit
tumour invasion and metastasis, even in ER-a-negative cells
(Meng et al, 2000a, 2001; Bonnesen et al, 2001; Chen et al, 2001).
Indole-3-carbinol downregulates expression of a G1 cyclin-
dependent kinase (CDK6) and upregulates a CDK inhibitor
(p21
Cip1) (Cover et al, 1998). The major active metabolite
of I3C, diindolylmethane (DIM), induces expression of GADD45a,
a DNA damage-responsive gene and putative tumour suppressor
(Carter et al, 2002). Indole-3-carbinol can activate two pathways
linked to cancer prevention: (1) aryl hydrocarbon receptor (AhR)
signalling (which leads to expression of phase I enzymes (e.g.,
CYP1A1) via the xenobiotic response element) and (2) anti-
oxidant/electrophilic response element signalling (resulting in
expression of phase II detoxifying enzymes: e.g., oxido-reductases
and glutathione-S-transferases) (Chen et al, 1998; Hayes and
McMahon, 2001; Kwak et al, 2002). Thus, the ability of I3C to
induce enzymes that metabolise genotoxic agents may contribute
to cancer prevention.
The ability of I3C and DIM to inhibit growth of human prostate
cancer cells has raised interest in I3C for prostate cancer
prevention. Thus, DIM inhibited dihydrotestosterone (DHT)-
stimulated cell proliferation and DHT-induced activation of the
prostate-specific antigen promoter in LNCaP cells, by acting as an
AR antagonist (Le et al, 2003). Indole-3-carbinol induced growth
arrest by upregulation of G1 cell cycle inhibitors (p21
Cip1 and
p27
Kip1) in androgen-independent PC-3 prostate cancer cells
(Chinni et al, 2001). Indole-3-carbinol and DIM can induce
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sp53-independent apoptosis in prostate cancer cells, in part, due to
inhibition of the NF-kB and c-Akt signalling pathways (Chinni
et al, 2001; Nacheson-Kedmi et al, 2003).
We have shown that I3C upregulates expression of the breast
cancer susceptibility gene-1 (BRCA1) (Meng et al, 2000ab,
2001; Carter et al, 2002). Here, we report that: (1) both I3C
and genistein, a soy isoflavone with cancer preventive activity
for prostate cancer and other tumour types, upregulate both
BRCA1 and BRCA2; (2) the BRCA genes contribute to some
functional activities of I3C and genistein; and (3) BRCA induction
may be due, in part, to stimulation of endoplasmic reticulum
stress signalling. These findings have implications for under-
standing the mechanism(s) of action of these phytochemical
cancer prevention agents.
MATERIALS AND METHODS
Sources of reagents
Indole-3-carbinol and genistein were obtained from the Sigma
Chemical Co. (St Louis, MO, USA) and dissolved in a small amount
of dimethylsulphoxide (DMSO) prior to dilution in cell culture
medium. 17b-Estradiol and DHT were also purchased from Sigma.
Thapsigargin and tunicamycin were obtained from Sigma,
dissolved in DMSO, and stored at  201C.
Cell lines and culture
Human breast (MCF-7 and T47D) and prostate (DU-145, PC-3, and
LNCaP) cancer cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). All cell lines except
LNCaP were grown in Dulbecco’s modified Eagle’s medium
(DMEM) plus 5% (MCF-7, DU-145, and PC-3) or 10% (T47D)
(vv
 1) fetal calf serum, L-glutamine (5mM), nonessential amino
acids (5mM), penicillin (100Uml
 1), and streptomycin
(100mgml
 1) (BioWhittaker, Walkersville, MD, USA). LNCaP cells
were grown in RPMI 1640 medium plus 10% fetal calf serum and
the above additives. Standard cell culture methodology was
employed (Fan et al, 1998, 2001a,b).
Expression vectors and reporter plasmids
Wild-type BRCA1 (wtBRCA1) cDNA, cloned into the pcDNA3
expression vector (Invitrogen), was described earlier (Fan et al,
1998). To express BRCA2, a full-length human BRCA2 cDNA
(provided by Dr Qingshen Gao, New England Medical
Center, Boston, MA, USA) was cloned into the pCMV-Tag2B
vector (Stratagene). The human ER-a expression vector and the
oestrogen-responsive reporter ERE-TK-Luc were described
before (Fan et al, 1999b, 2001a). Wild-type AR expression
vector pSG5-AR and the androgen-responsive reporter
plasmid ARE-TK-Luc were provided by Dr Chawshang Chang
(University of Rochester, Rochester, NY, USA). The ARE-TK-Luc
reporter contains an androgen-response element upstream
of a minimal thymidine kinase (TK) promoter driving the
luciferase gene.
Luciferase reporters driven by the wild-type endoplasmic
reticulum stress-response element (ERSEwt-Luc), a mutant ERSE
(ERSEmut-Luc, a negative control), and the ERSE-II element
(ERSEII3x-Luc) in the pGL3 vector were generously provided by
Dr Kazutoshi Mori (HSP Research Institute, Kyoto Research Park,
Kyoto, Japan) (Yoshida et al, 1998; Yamamoto et al, 2004). A
CHOP (C/EBP homologous protein) promoter-luciferase reporter
in the pGL3 vector (CHOP-Luc) was provided by Dr Pierre
Fafournoux (Unite de Nutrition et Metabolisme Proteique, INRA
de Theix, Saint Genes Champanelle, France) (Bruhat et al, 2000). A
dominant negative (DN) PERK expression vector in the pcDNA3
vector (DN-PERK) was kindly provided by Dr Annette C Dolphin
(University College London, London, UK) (Page et al, 2004). The
DN-ATF4 expression vector was provided by Dr Steve F Abcouwer
(University of New Mexico School of Medicine, Albuquerque, NM,
USA) (Roybal et al, 2004), while the DN-IRE1 expression vector
was provided by Dr David Ron (Skirball Institute of Biomolecular
Medicine, New York University School of Medicine, New York,
NY, USA) (Wang et al, 1998).
Cell viability (MTT) assays
Cell viability was determined following the treatments indicated
in the figure legends, as described earlier (Fan et al, 1998,
1999a). For siRNA treatments, subconfluent proliferating cells in
96-well dishes were transfected with BRCA1 or BRCA2 siRNA
(50nM 72h; see below), or mock-treated (transfection reagent
only); exposed to different doses of I3C (or vehicle (DMSO) only)
for 24h; and then assayed for MTT dye reduction. For over-
expression experiments, the cells were transfected overnight with
wtBRCA1 or wtBRCA2 expression vectors (0.06mg plasmid DNA
per well), washed, and postincubated for another 24h to allow gene
expression, prior to exposure to I3C. Cell viability was expressed
relative to control cells treated with DMSO only (0 I3C) as
mean7s.e.m. of 10 replicate wells.
Knockdown of BRCA1 or BRCA2 using small interfering
RNAs (siRNAs)
The BRCA1-siRNA and control (scrambled sequence) siRNAs were
described earlier (Xiong et al, 2003). All siRNAs were chemically
synthesised by Dharmacon, Inc. For siRNA treatments, subcon-
fluent proliferating cells were transfected with 50nM of siRNA
using the siPORT Amine transfection reagent (Ambion). For both
BRCA1 and BRCA2, maximal reduction of protein levels required a
72-h incubation with the siRNA. Prior studies have established that
under these conditions, none of the siRNAs caused cytotoxicity,
based on cell morphology and MTT assays. The sequences used to
synthesise the siRNAs are listed below:
BRCA1-siRNA 50-AATGCCAAAGTAGCTAATGTA-30
Control-siRNA 50-CGATAGATACACAGATTGAAT-30
BRCA2-siRNA 50-AACTGAGCAAGCCTCAGTCAA-30
Oestrogen receptor-a transcriptional activity assay
Oestrogen receptor-a activity was measured via transient transfec-
tion assays, using an oestrogen-responsive luciferase reporter (Fan
et al, 1999b, 2001a). Briefly, subconfluent proliferating cells in 24-
well dishes were cotransfected overnight with a wild-type ER-a
expression vector (pSG5-ER-a) and the ERE-TK-Luc reporter
(0.25mg of each plasmid per well), in the presence of Lipofecta-
minet (Life Technologies, Carlsbad, CA, USA). The cells were
washed to remove the excess plasmid and Lipofectamine; allowed
to recover for several hours; and postincubated for 24h in phenol
red-free medium containing 2% charcoal-stripped fetal calf serum,
with the indicated agents (17-b-estradiol (E2, 1mM) and/or I3C
and/or genistein). The doses of each agent are indicated in the
figures. Luciferase activity was determined; and the values were
expressed relative to the positive control (þE2, no I3C or
genistein), as means7s.e.m.’s of three independent experiments,
with each assay condition tested in four replicate wells per
experiment. To monitor transfection efficiency, cells were co-
transfected with control plasmid pRSV-b-gal to allow measure-
ment of b-galactosidase activity.
Androgen receptor (AR) transcriptional activity assays
Androgen receptor activity was measured via transient transfec-
tion assays, using an androgen-responsive reporter (ARE-TK-Luc).
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sAssays were performed as described above, except that AR-
negative PC-3 cells were cotransfected with a wild-type human AR
expression vector (pSG5-AR); and the cells were stimulated with
DHT (10nM) for 24h, again in the absence or presence of the
specified doses I3C or genistein. The expression of luciferase
activity and the number of replicate assays were the same as
described above. Each experiment was repeated at least twice to
assure reproducibility.
mRNA assays
mRNA expression was determined by rigorously controlled
semiquantitative RT–PCR assays. For each amplified product,
the PCR reaction conditions and cycle numbers were individually
adjusted so that all reactions occurred within the linear range of
product amplification. The detailed methods for RNA isolation,
cDNA synthesis, and RT–PCR analyses for BRCA1, BRCA2, and
b-actin (control gene) have been described before (Fan et al,
1998, 1999a; Xiong et al, 2003). For AR, the PCR primers were as
follows: 50-TGTTTTCCCCCTCTTCCTT-30 (forward) and 50-
TCCTTTTTTCCAGCATAGACC-30 (reverse). The PCR products
were analysed by electrophoresis through 0.8% agarose gels
containing 0.1mgml
 1 of ethidium bromide, and the gels were
photographed under ultraviolet light. The mRNA levels were
quantitated by densitometry of the cDNA bands and expressed
relative to b-actin. At least two independent experiments were
performed for each cell type studied.
Protein assays
Cell lysates were prepared and Western blotting was performed
as described earlier (Fan et al, 1998, 1999a). Equal aliquots of
total cell protein (50mg per lane) were electrophoresed on
SDS–polyacrylamide gradient gels, transferred to nitrocellulose
membranes (Millipore, Billerica, MA, USA), and blotted using
these primary antibodies: BRCA1 (C-20, rabbit polyclonal, Santa
Cruz Biotechnology, 1:200); BRCA2 (C-19, Santa Cruz, 1:200);
and actin (I-19, goat polyclonal, Santa Cruz, 1:500). The proteins
bands were visualised using the enhanced chemiluminescence
system (Amersham), with coloured markers (BioRad) as molecular
size standards. Protein bands were quantitated by densitometry,
and the values were expressed relative to actin (control for loading
and transfer). At least two independent experiments were
performed for each cell type studied.
Statistical comparisons
Where appropriate, statistical comparisons of the experimental
results were made using the two-tailed Student’s t-test.
RESULTS
Indole-3-carbinol upregulates BRCA1 and BRCA2
expression in breast and prostate cancer cells
We previously showed that I3C stimulates BRCA1 expression
in human cervical and breast cancer cells (Meng et al, 2000a,b,
2001; Carter et al, 2002). Here, we tested the effect of I3C on
BRCA1 and BRCA2 expression in breast and prostate cancer
cells. Using rigorously controlled semiquantitative RT–PCR
and densitometry analysis, we found that a dose of I3C (60mM)
that causes little or no cytotoxicity caused a time-dependent
increase in BRCA1 and BRCA2 mRNA levels in two breast
cancer cell lines, MCF-7 and T47D (Figure 1A and B). BRCA1
levels were increased at the earliest time point tested (1h),
reached near maximum by 6–8h, and were still elevated at 48h.
For T47D, BRCA2 mRNA levels were also elevated by 1–2h and
remained elevated throughout the experiment. MCF-7 cells also
showed strong time-dependent induction of BRCA2 by I3C,
but consistent increases in BRCA2 mRNA levels were only
observed at 6h and later. Indole-3-carbonil caused dose-dependent
induction of BRCA1 and BRCA2 mRNA (measured at 24h)
starting at 20–40mM (Figure 1C and D). Little or no changes in
expression of the control gene (b-actin) were evident in any of
these experiments.
We tested the effect of I3C on BRCA protein levels by Western
blotting with quantitation of the protein bands by densitometry.
BRCA protein levels were upregulated by I3C in a time- and dose-
dependent fashion in breast (MCF-7 and T47D) and prostate
(LNCaP and DU-145) cancer cells (Figure 2). For the breast cancer
cells, increased BRCA2 protein levels were first observed after
4–8h of I3C (60mM); while increases in BRCA1 levels were
detected earlier, but were relatively small in magnitude at early
time points (Figure 2A and B). The dose–response studies of MCF-
7 and T47D cells revealed significant induction (42-fold) of
BRCA1 and BRCA2 protein levels at the lowest dose of I3C tested,
20mM (Figure 2C and D). In Figure 2C, the BRCA2 protein
induction is not the same as that of the mRNA (Figure 1C). This
may be due to inaccuracies in the densitometry quantitation of
the RT–PCR (especially when bands are weak), the fact that the
protein and mRNA experiments were performed at different times,
or the fact that I3C might have an additional effect on protein
stability, which we cannot rule out.
Time course studies of prostate cancer cell lines showed
a delay in the induction of BRCA2 by I3C (first observed
at 6h) relative to that of BRCA1 (1h) (Figure 2E and F).
As for breast cancer cells, BRCA1 and BRCA2 levels were
increased by X2-fold at the lowest dose of I3C (20mM) (Figure
2G and H). Although there was some variability from cell
line to cell line, these studies show reproducible induction of
BRCA1 and BRCA2 by I3C, with increases in BRCA1 and BRCA2
protein levels at an I3C dose of 60mM at 24h of (5–10)-fold for the
breast cancer cell lines and (8–16)-fold for the prostate cancer cell
lines. Note: In the studies shown in Figures 1 and 2, the
densitometry values are the means of at least two independent
experiments.
Genistein upregulates BRCA1 and BRCA2 expression
Genistein is a soy isoflavone that functions, in part, as a
phytoestrogen and a phytoandrogen (Wang et al, 1996; Maggiolini
et al, 2002). Since genistein is proposed as a chemoprevention
agent for several tumour types (Mentor-Marcel et al, 2001;
Lamartiniere et al, 2002), including breast and prostate cancers,
we tested its ability to induce BRCA expression. Genistein caused
dose- and time-dependent increases in BRCA1 and BRCA2 protein
levels in two oestrogen-responsive breast cancer cell lines (MCF-7
and T47D) (Figure 3D). Induction of BRCA1 occurred after 1h of
genistein exposure (5mM); while the induction of BRCA2 was
delayed until 6–8h (Figure 3A and B). For both cell lines, increases
in BRCA1 levels of 42-fold were observed at the lowest dose of
genistein tested (0.5mM); while similarly robust increases in
BRCA2 levels required higher genistein doses (1–2.5mM) (Figure
3C and D).
Genistein also caused time- and dose-dependent increases
in BRCA levels in androgen-sensitive (LNCaP) and insensitive
(DU-145) prostate cancer cells. For these cell lines, increases in
BRCA1 levels of X 2-fold occurred at 1h; while similar increases
in BRCA2 levels occurred at 4–8h (Figure 3E and F). When
measured at 24h, significant increases in BRCA1 levels required
doses of 0.5–1.0mM; while increases in BRCA2 levels required
2.5mM of genistein (Figure 3G and H). Increases in BRCA levels
after exposure to 5mM of genistein for 24h ranged (4–12)-fold for
breast cancer cells and (5–17)-fold for prostate cancer cells. The
densitometry values in Figure 3 are the means of at least two
independent experiments.
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Figure 1 Indole-3-carbinol (I3C) upregulates BRCA1 and BRCA2 mRNA expression in human breast cancer cells in a time- and dose-dependent manner.
For time course studies, subconfluent proliferating MCF-7 (A) or T47D (B) cells were treated with I3C (60mM) for different times and harvested for mRNA
analysis by semiquantitative RT–PCR. For dose–response studies, MCF-7 (C) or T47D (D) cells were treated with different doses of I3C for 24h and
harvested for mRNA analysis. The PCR bands were quantified by densitometry and expressed relative to the control gene, b-actin. The densitometry values
are means7s.e.m.’s of at least two independent experiments.
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Figure 2 Indole-3-carbinol upregulates BRCA1 and BRCA2 protein levels in human breast and prostate cancer cells in a time- and dose-dependent
manner. For time course studies, subconfluent proliferating MCF-7 (A), T47D (B), DU-145 (E), and LNCaP (F) cells were treated with I3C (60mM) for
various times and harvested for Western blot analysis to detect the BRCA1, BRCA2, or actin (control for loading and transfer) proteins. For dose–response
studies, MCF-7 (C), T47D (D), DU-145 (G), or LNCaP (H) cells were treated with the indicated dose of I3C for 24h and then assayed for BRCA1 and
BRCA2 protein expression. The protein bands were quantitated by densitometry and expressed relative to actin. The densitometry values are
means7s.e.m.’s of at least two independent experiments.
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sRole of BRCA1 in the induction of BRCA2 by I3C and by
genistein
Several factors suggest that the phytochemical induction of BRCA2
is due, in part, to BRCA1. Thus, BRCA1 and BRCA2 are
coordinately regulated during development and during cell cycle
progression (Rajan et al, 1996, 1997); and exogenous BRCA1
upregulates expression of BRCA2 in cultured cells (Fan et al, 1998).
BRCA1 and BRCA2 are also coregulated in response to
DNA-damaging agents and other cytotoxins (Andres et al, 1998;
Fan et al, 1999a). To determine the role of BRCA1 in the
induction of BRCA2, we utilised specific BRCA1 and BRCA2
siRNAs. The BRCA1-siRNA was validated in a prior study
(Xiong et al, 2003). As illustrated in Figure 4A, a single application
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Figure 3 Genistein upregulates BRCA1 and BRCA2 protein levels in breast cancer cells. For time course studies, subconfluent proliferating MCF-7 (A),
T47D (B), DU-145 (E), and LNCaP (F) cells were treated with genistein (5mM) for the indicated times and harvested for Western blotting to detect the
BRCA1, BRCA2, or actin proteins. For dose–response studies, MCF-7 (C), T47D (D), DU-145 (G), or LNCaP (H) cells were treated with the indicated
dose of genistein for 24h and assayed for BRCA1 and BRCA2 protein expression, as described above. The densitometry values represent means7s.e.m.’s
of at least two independent experiments.
BRCA genes as targets for phytochemicals
S Fan et al
413
British Journal of Cancer (2006) 94(3), 407–426 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sof 50nM of BRCA1-siRNA caused a loss of BRCA1 and BRCA2
proteins by 48–72h, while a control-siRNA had no effect on
BRCA1 or BRCA2 levels.
Consistent with these findings, BRCA1-siRNA caused loss of
BRCA1 and BRCA2 proteins in DU-145 cells, but the converse was
not true (Figure 4B). Thus, BRCA2-siRNA caused loss of BRCA2
protein, but BRCA1 was unaffected or only slightly decreased
(Figure 4B). The control-siRNA had little or no effect on BRCA1 or
BRCA2. In overexpression studies, a wild-type (wt) BRCA1
expression vector caused significant induction of BRCA2 levels;
E
F
G
H
LNCaP
LNCaP
DU-145
DU-145
Actin
(43 kDa)
BRCA1
(220 kDa)
BRCA1
BRCA2
BRCA1
BRCA2
BRCA1
BRCA2
BRCA1
BRCA2
BRCA2
(380 kDa)
Time after addition of genistein (h)
Time after addition of genistein (h)
01468 1 6 2 4 4 8
Actin
(43 kDa)
Actin
(43 kDa)
BRCA1
(220 kDa)
BRCA2
(380 kDa)
BRCA1
(220 kDa)
BRCA2
(380 kDa)
Actin
(43 kDa)
BRCA1
(220 kDa)
BRCA2
(380 kDa)
Time after addition of genistein (h)
014 68 16 24 48
0 4 8 16 12 24 48
Time after addition of genistein (h)
0 4 8 16 12 24 48
P
r
o
t
e
i
n
/
a
c
t
i
n
 
r
a
t
i
o
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
P
r
o
t
e
i
n
/
a
c
t
i
n
 
r
a
t
i
o
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
1200
1500
1800
900
1200
1500
900
600
600
300
300
100
0
P
r
o
t
e
i
n
/
a
c
t
i
n
 
r
a
t
i
o
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
1200
1500
1800
900
600
300
0
P
r
o
t
e
i
n
/
a
c
t
i
n
 
r
a
t
i
o
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
1200
1500
1800
900
600
300
0
0
0 0.5 1 2.5 5 7.5
Genistein dose (M)
0 0.5 1 2.5 5 7.5
0 0.5 1 2.5 5 7.5
Genistein dose (M)
Genistein dose (M)
0 0.5 1 2.5 5 7.5
Genistein dose (M)
Figure 3 (Continued)
BRCA genes as targets for phytochemicals
S Fan et al
414
British Journal of Cancer (2006) 94(3), 407–426 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swhereas wtBRCA2 caused a more modest rise in BRCA2 levels
(Figure 4C). Next, we tested the role of BRCA1 in the induction of
BRCA2 levels by I3C and by gensitein. In DU-145 cells pretreated
with BRCA1-siRNA, there was little or no detectable BRCA2 in
control, I3C-treated, or genistein-treated cells (Figure 4D and E,
respectively). In cells treated with BRCA2-siRNA, BRCA2 was
nearly undetectable in control and phytochemical-treated cells.
However, BRCA1 was significantly induced by both I3C and
genistein. A control-siRNA had no effect on the expression or
induction of BRCA proteins. These findings suggest that the
induction of BRCA2 by phytochemicals is dependent, in part, upon
BRCA1, but not vice versa.
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Figure 4 Dependence of phytochemical-induced expression of BRCA2 on BRCA1. (A) BRCA1-siRNA causes time-dependent loss of BRCA1 and
BRCA2 in MCF-7 cells. Subconfluent proliferating cells were treated with BRCA1-siRNA (left) or control-siRNA (right) (50nM) for different times, harvested,
and Western blotted for BRCA1, BRCA2, and actin. (B) Effect of BRCA1-siRNA on BRCA2 protein levels and vice versa in DU-145 cells. Cells were treated
with BRCA1, BRCA2, or control-siRNA (50nM) for 72h and Western blotted for BRCA1, BRCA2, and actin. Results are shown for two separate cell
treatments and protein isolations on the same blot. (C) Effect of wtBRCA1 on BRCA2 protein levels and vice versa in DU-145 cells. Cells were transfected
overnight with wtBRCA1, wtBRCA2, or empty pcDNA3 vector, washed, postincubated for 24h to allow gene expression, harvested, and Western blotted
for BRCA1, BRCA2, and actin. Results are shown for two separate cell treatments and protein isolations on the same blot. The densitometry values are
means7ranges of two experiments. (D) Effect of BRCA1 and BRCA2 siRNAs on BRCA induction by I3C. DU-145 cells were preincubated with the
indicated siRNA (50nM 72h) or no siRNA (transfection reagent only), then treated with I3C (40mM) for 24h, and then harvested for Western blotting.
(E) Effect of BRCA1 and BRCA2 siRNA on induction of BRCA1 and BRCA2 by genistein. DU-145 cells were preincubated with the indicated siRNA
(50nM 72h), treated with genistein (5mM) for 24h, and harvested for Western blotting as above. (F) Induction of BRCA1 and BRCA2 by a combination of
I3C plus genistein. MCF-7 or DU-145 cells were treated with low doses of I3C (25mM) and/or genistein (1mM) for 24h and harvested for Western blotting.
The densitometry values are means7ranges of two independent experiments. (G) Effect of ICI182,780 on phytochemical induction of BRCA1 in MCF-7
cells. Proliferating cells were incubated with the indicated agents for 24h and then harvested for Western blotting for BRCA1, ER-a, or actin. (H) Effect of
BRCA1 knockdown and phytochemicals on ER-a protein levels. MCF-7 cells were pretreated with BRCA1 or control siRNA as described above, exposed to
the indicated doses of I3C or genistein for 24h, and then Western blotted for ER-a, BRCA1, or actin.
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We tested the effects of a combination of low doses of I3C (25mM)
and genistein (1mM) on BRCA protein levels in MCF-7 and DU-145
cells. The combination of (I3Cþgenistein) had a greater effect on
BRCA induction than either agent alone (Figure 4G). These effects
appeared to be supra-additive or synergistic for BRCA1 in MCF-7
cells and for BRCA2 in both cell types, although we did not
perform studies using a range of different doses. Thus, 1mM of
genistein by itself caused only a modest increase in BRCA2 levels;
but the combination of (I3Cþgenistein) caused a much larger
increase in BRCA2 levels than did I3C alone.
Effect of inhibition of ER-a on BRCA1 expression
To determine if ER-a might have a role in the induction of BRCA1
by phytochemicals, MCF-7 cells were treated with I3C or genisetin
in the absence or presence of ICI182,780 (Fulvestrant), an anti-
oestrogen that causes degradation of ER-a. Here, ICI182,780
caused loss of ER-a protein but had no effect on the ability of I3C
or genistein to induce BRCA1 protein (Figure 4G). As illustrated in
Figure 4H, neither BRCA1-siRNA, nor I3C, nor genistein had ER-a
protein levels in MCF-7 cells. Taken together with the findings that
I3C and genistein can induce BRCA expression in ER-a-negative
cell types (e.g., DU-145), these results suggest that the induction of
BRCA expression by phytochemicals is not mediated through the
oestrogen receptor.
Role of BRCA1 in mediating some biological actions of I3C
and genistein
While it is clear that I3C and genistein induce BRCA gene
expression in human cancer cells, the roles of the BRCA genes in
mediating the biologic responses to these phytochemicals is not
established. We tested these roles utilising the BRCA1 and BRCA2
siRNA and other reagents.
Cytotoxicity At high doses (X100mM), I3C causes cytotoxicity
and apoptosis in cancer cell lines (Chen et al, 2001; Chinni et al,
2001; Rahman et al, 2003; Sarkar et al, 2003). Exogenous BRCA1
causes increased susceptibility to apoptosis due to DNA-damaging
agents (e.g., adriamycin), although wtBRCA1 does not induce
apoptosis by itself (Fan et al, 1998, 2001b). We tested the effect of
manipulating BRCA levels on I3C cytotoxicity using MTT assays.
Figure 5A shows the ability of BRCA1-siRNA and BRCA2-siRNA to
reduce BRCA1 and BRCA2 protein levels, respectively, by 48–72h.
In three different cell lines (MCF-7, T47D, and DU-145), we found
that BRCA1-siRNA protected cells against I3C cytotoxicity (Figure
5C, E and G). BRCA1-siRNA-treated cells usually showed survival
rates about 1575% higher than control-siRNA-treated cells
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s(Po0.001, two-tailed t-tests), although the degree of protection by
BRCA1-siRNA was greater for DU-145 cells at 300–400mM of I3C
(21–32%).
In contrast, cells transfected with a wtBRCA1 gene were more
sensitive to I3C than control cells (Po0.001) (Figure 5B, D, and F).
At 200–400mM of I3C, MCF-7 and T47D cells transfected with
100
80
60
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
40
20
I3C (M)
Control
pCMV-Tag2B
wtBRCA1
Control
pCMV-Tag2B
wtBRCA1
Control
Control siRNA
BRCA1-siRNA
B
R
C
A
1
-
s
i
R
N
A
B
R
C
A
1
-
s
i
R
N
A
Control
Control siRNA
BRCA1-siRNA
0
100
80
60
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
40
20
0
100
80
60
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
40
20
0
100
80
60
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
40
20
0
0 100 200 300 400 500
I3C (M)
0 100 200 300 400 500
I3C (M)
0 100 200 300 400 500
I3C (M)
0 100 200 300 400 500
MCF-7
MCF-7
T-47D
BRCA1
(220 kDa)
Actin
(43 kDa)
BRCA2 
(380 kDa)
Actin
(43 kDa)
48 72 (h)
C
o
n
t
r
o
l
C
o
n
t
r
o
l
A
BC
DE
Figure 5 Contribution of BRCA1 and BRCA2 to I3C-mediated cytotoxicity. (A) The effects of BRCA1-siRNA (48 and 72h) and BRCA2-siRNA (72h)
(50nM) on BRCA1 and BRCA2 protein levels, respectively, in MCF-7 cells. MCF-7 (B and C), T47D (D and E), and DU-145 (F and G) cells were
experimentally manipulated to increase (wtBRCA1) or decrease (BRCA1-siRNA) BRCA1 levels, treated with different doses of I3C, and tested for cell
viability using MTT assays. In (H) and (I), DU-145 cells were manipulated to increase (wtBRCA2) or decrease (BRCA2-siRNA) BRCA2 levels, exposed to
different doses of I3C, and tested for cell viability using MTT assays. Methodology (B–I). To increase BRCA1 levels, subconfluent cells in 96-well dishes were
transfected with wtBRCA1 overnight (see Materials and Methods), washed, postincubated for 24h, exposed to different doses of I3C for 24h, and assayed
for MTT dye reduction. To decrease BRCA1 levels, cells were pretreated with BRCA1- or control-siRNA (50nM 72h) or mock-transfected (control) and
assayed for sensitivity to I3C as above. For BRCA2 experiments, DU-145 cells were transfected with wtBRCA2 or treated with BRCA2- or control-siRNA
(as above) and assayed as described above for sensitivity to I3C. Cell viability values are expressed relative to the 0 I3C control and are means7s.e.m.’s for
10 replicate wells. Statistical comparisons. Cell viability comparisons were made using two-tailed t-tests. Significant differences were as follows: MCF-7
wtBRCA1 vs control, Po0.001 at 100–400mM I3C; MCF-7 BRCA1-siRNA vs control, Po0.001 at 200–500mM I3C; T47D wtBRCA1 vs control, Po0.001
at 100–500mM I3C; T47D BRCA1-siRNA vs control, Po0.001 at 200–500mM I3C; DU-145 wtBRCA1 vs control, Po0.001 at 100–400mM I3C; DU-145
BRCA1-siRNA vs control, Po0.001 at 100–500mM I3C; DU-145 wtBRCA1 vs control, Po0.001, 100–400mM I3C; and DU-145 BRCA2-siRNA vs control,
Po0.001 at 200–500mM I3C.
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swtBRCA1 showed survival rates about 15–20% lower than control-
transfected cells; while wtBRCA1-transfected DU-145 cells showed
15–40% lower survival than control-transfected cells at 100–
400mM I3C. These findings suggest that BRCA1 modulates the
cytotoxicity of I3C and that endogenous BRCA1 contributes the
cytotoxicity of I3C.
Since the BRCA1-siRNA downregulates BRCA2 levels, we tested
the ability of BRCA2 to modulate sensitivity to high doses of I3C.
As was true for BRCA1, a wtBRCA2 expression vector sensitised
DU-145 cells to I3C (Figure 5H); while BRCA2-siRNA conferred
decreased sensitivity to I3C (Po0.001 at all doses) (Figure 5I).
Taken together with the previous results, these findings suggest
that (1) both BRCA genes modulate cellular sensitivity to I3C and
(2) the modulation of sensitivity to I3C by BRCA1 is due, in part,
to alterations in BRCA2 levels.
Oestrogen receptor–a signalling We showed that I3C causes dose-
dependent inhibition of estradiol (E2)-stimulated ER-a activity in
cervical and breast cancer cells, by the use of an E2-responsive
reporter (ERE-TK-Luc) and by testing the effect of I3C on
expression of endogenous E2-responsive genes (Meng et al,
2000b). Since wtBRCA1 strongly inhibits ER-a signalling (Fan
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Figure 5 (Continued)
Figure 6 Contribution of BRCA genes to regulation of ER-a and AR activity by I3C and genistein. (A) Rescue of I3C inhibition of E2-stimulated ER-a
activity by BRCA1-siRNA. MCF-7 cells were pretreated with BRCA1-siRNA, BRCA2-siRNA, control-siRNA (50nM 72h), or no siRNA (vehicle only).
After the first 48h of siRNA treatment, they were transfected with the ERE-TK-Luc reporter overnight, washed, postincubated717b-estradiol (E2, 1mM)
and 7I3C (100mM) for 24h, and tested for luciferase activity. Values are expressed relative to the þE2 positive control (no siRNA, no I3C) and are
means7s.e.m.’s of three independent experiments. In each experiment, each assay condition was tested in four replicate wells, and the values were
averaged. BRCA1 (but not BRCA2 or control) siRNA reversed the inhibition of E2-stimulated ER-a activity by I3C (Po0.001). (B) Rescue of genistein
inhibition of E2-stimulated ER-a activity by BRCA1-siRNA. The experiment was performed as described above, except that the cells were treated
7genistein (5mM) instead of I3C. Luciferase values are expressed relative to the þE2 positive control (no siRNA, no genistein) and are means7s.e.m.’s of
three independent experiments, with each assay condition tested in four replicate wells per experiment. BRCA1 (but not BRCA2 or control) siRNA
reversed the inhibition of E2-stimulated ER-a activity by genistein (Po0.001). (C, D) Contribution of BRCA1 to inhibition of DHT-stimulated AR activity by
I3C and genistein. LNCaP (C) or PC-3 (D) cells were pretreated with BRCA1-siRNA, control-siRNA (50nM 72h), or no siRNA. LNCaP cells, which are
AR-positive, were transfected with an androgen-responsive reporter (ARE-TK-Luc); while PC-3 cells, which are AR-negative, were cotransfected with an AR
expression vector plus ARE-TK-Luc. The cells were treated with dihydrotestosterone (DHT, 10nM), I3C (25mM), and/or genistein (1.0mM) for 24h and
assayed for luciferase activity. BRCA1-siRNA enhanced DHT-stimulated AR activity and partially rescued the inhibition of AR activity by I3C and genistein
(left panels). The asterisks indicate a significant comparison (Po0.01). (E) Effect of BRCA1-siRNA and phytochemicals on AR protein levels in LNCaP cells.
Cells were pretreated with BRCA1 or control siRNA and then treated with I3C, genistein, or DHT as described in (C). The cells were then harvested and
Western blotted for AR or actin. (F) Effect of BRCA1-siRNA on AR mRNA levels. LNCaP cells were pretreated with BRCA1- or control-siRNA, treated
with DHT for 24h, and harvested for semiquantitative RT–PCR to detect BRCA1, AR, or b-actin.
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set al, 1999b), we hypothesised that BRCA1 might contribute to the
inhibition of ER-a activity by I3C. Thus, we assayed the effects of
BRCA siRNAs on the ability of I3C and genistein to inhibit E2-
stimulated ER-a activity (Figure 6). While genistein is called a
‘phytoestrogen’ because it has weak oestrogenic activity in the
absence of E2, it acts as an inhibitor of ER-a in the presence of E2.
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sThus, genistein caused dose-dependent inhibition of E2-stimulated
ER-a activity in MCF-7 cells (data not shown). In this study, we did
not observe pro-oestrogenic effects of genistein. However, we did
not specifically test conditions that would elicit such effects.
Figure 6A shows the effect of pretreatment with BRCA siRNAs
on inhibition of E2-stimulated ER-a activity by I3C. These data are
the means7s.e.m.’s of three independent experiments. BRCA1
(but not BRCA2) siRNA caused a modest increase in E2-stimulated
ER-a activity. Under conditions in which I3C caused 490%
inhibition of ER-a activity, pretreatment with BRCA1-siRNA (but
not BRCA2- or control-siRNA) substantially restored E2-stimu-
lated ER-a activity (Po0.001, two-tailed t-test). Similar results
were obtained using genistein (Figure 6B). Thus, BRCA1 (but not
BRCA2 or control) siRNA significantly reversed the genistein-
mediated inhibition of E2-stimulated ER-a activity (Po0.001).
Previously, we identified an N-terminal fragment of the BRCA1
protein (amino acids 1–302) that functioned as a DN inhibitor of
the full-length wild-type BRCA1 and ‘rescued’ the wtBRCA1-
mediated inhibition of ER-a activity (Fan et al, 2001a,b). Here, we
found that transient transfection of a BRCA1 amino acid 1–302
expression vector (DN-BRCA1) partially rescued the inhibition of
E2-stimulated ER-a activity by I3C alone, genistein alone, or the
combination of I3C plus genistein (Po0.001) (data not shown).
These findings suggest that the inhibition of E2-stimulated ER-a
activity by I3C and genistein is due, in part, to BRCA1.
AR signalling Both I3C and genistein can interact with and
modulate the AR. Thus, I3C is an AR antagonist (Le et al, 2003),
while genistein can activate the AR in the absence of ligand but
inhibit DHT-induced AR activity (Maggiolini et al, 2002). We
tested the role of BRCA1 in mediating the effects of low doses
of I3C (25mM) or genistein (1mM) on AR signalling. We studied
LNCaP cells (an androgen-responsive cell line) using their
endogenous AR and PC-3 (an androgen-insensitive cell line)
using transiently expressed wild-type AR. Consistent with
published findings, genistein (but not I3C) caused a modest
activation of an androgen-responsive reporter (ARE-TK-Luc) in
the absence of DHT (Figure 6C and D, right panels), while both I3C
and genistein caused inhibition of DHT-stimulated AR activity
(Po0.001) (Figure 6C and D, left panels). Interestingly, pretreat-
ment with BRCA1-siRNA caused an increase in DHT-stimulated
AR activity (relative to control-siRNA or vehicle-treated cells) in
the absence of I3C or genistein and partially rescued the inhibition
of AR activity by I3C and genistein (Po0.01). Similar results were
observed in LNCaP and PC-3 cells. Pretreatment with BRCA1-
siRNA caused an increase in AR protein levels in cells treated with
DHT, whereas BRCA1-siRNA by itself and control-siRNA in the
absence or presence of DHT had little or no effect on AR levels
(Figure 6E). In contrast, BRCA1-siRNA had no effect on AR mRNA
levels in the presence of DHT (Figure 6F). The implications of
these findings are considered in the Discussion.
Role of endoplasmic reticulum stress in induction of BRCA
expression
Agents that cause endoplasmic reticulum stress induce BRCA
expression A recent study showed that DIM, a major metabolite
of I3C, causes an endoplasmic reticulum-like stress response,
similar to the unfolded protein response in yeast (Sun et al, 2004).
Diindolylmethane caused phosphorylation of eucaryotic transla-
tion initiation factor 2a (EIF2A) linked to increased levels of ATF4
protein; activation of IRE1 (the homologue of inositol-requiring 1);
a rapid increase in the stress-specific spliced form of XBP-1
mRNA; and induction of multiple stress-response genes, including
CHOP (or GADD153), GADD34, GADD45A, XBP-1, GRP78, and
GRP94 (Carter et al, 2002; Sun et al, 2004). Here, we tested the
ability of two agents known to cause an endoplasmic reticulum
stress response to induce BRCA expression. Incubation of T47D or
MCF-7 cells with thapsigargin, a selective inhibitor of the
endoplasmic reticulum Ca
þ2-dependent ATPase, caused dose-
and time-dependent induction of BRCA1 and BRCA2 mRNA
expression (Figure 7A–C). Induction of both BRCA genes
occurred after a 24-h incubation with doses as low as 50–100nM
of thapsigargin (Figure 7A and B), while a time course study
showed that BRCA1 mRNA was induced by thapsigargin (300nM)
after 4–6h, with BRCA2 mRNA induction occurring slightly later
(Figure 7C). MTT assays revealed no toxicity at thapsigargin doses
p300nM (data not shown). Western blotting revealed induction
of BRCA1 protein in T47D and MCF-7 cells at 50–100nM of
thapsigargin (Figure 7D and E).
We also saw dose-dependent induction of BRCA1 and BRCA2
proteins by tunicamycin (Figure 7F and G), an agent that causes an
endoplasmic reticulum stress response by inhibition of protein
glycosylation. These findings suggest that activation of an
endoplasmic reticulum stress response by two distinct agents
upregulates the expression of BRCA1 and BRCA2.
The ER stress-response kinase PERK is required for BRCA1
induction by I3C We tested the role of several endoplasmic
reticulum stress signalling proteins in I3C induction of BRCA1 and
BRCA2, using DN expression vectors. PERK (EIF2AK3) is a kinase
that phosphorylates EIF2A in response to endoplasmic reticulum
stress, causing inhibition of protein synthesis associated with the
accumulation of ATF4 protein (Rutkowski and Kaufman, 2003).
Transfection of a DN-PERK blocked the ability of I3C (100mM)t o
induce both BRCA1 and BRCA2 protein levels (Figure 8A).
However, a DN-ATF4 vector failed to inhibit I3C-induced BRCA1
and BRCA2 expression (Figure 8B). Finally, we tested the role of
IRE1 (the homolog of yeast inositol-requiring 1) – an endoplasmic
reticulum membrane-localised kinase and endoribonuclease that is
activated in response to stress (Shen et al, 2001) – in mediating
BRCA induction. Here, a DN-IRE1 vector failed to inhibit I3C-
induced BRCA1 or BRCA2 expression (Figure 8C). These findings
suggest that PERK, an upstream component of endoplasmic
reticulum and nutritional stress-response pathways, is required for
BRCA induction.
I3C, genistein, and BRCA1 stimulate endoplasmic reticulum stress
signalling Endoplasmic reticulum stress signalling is mediated,
in part, by transcription via cis-acting DNA elements in target
genes, including the endoplasmic reticulum stress-response
element (ERSE), unfolded protein response element (UPRE), and
a second type of ERSE (ERSE-II) (Yamamoto et al, 2004). We
tested the ability of I3C, genistein, and BRCA1 to stimulate
reporters driven by the wild-type ERSE (ERSEwt-Luc), a mutant
ERSE (ERSEmut-Luc, a negative control), and the ERSE-II element
(ERSEII3x-Luc). Figure 9A shows the ability of I3C and/or
tunicamycin to induce ERSE signalling in T47D and MCF-7 cells.
Each agent caused a significant induction of ERSEwt and ERSE-II
activity (Po0.001), but the ERSEmut-Luc reporter showed little or
no activity. Similarly, low doses of genistein (0.5 and 1.0mM)
significantly activated the ERSEwt and ERSE-II but not the
ERSEmut reporter (Po0.001) (Figure 9B). CHOP is a stress-
responsive transcriptional regulator implicated in apoptosis due
to severely impaired endoplasmic reticulum function (Oyadomari
and Mori, 2004). Indole-3-carbinol and genistein caused dose-
dependent activation of a CHOP-Luc reporter in T47D and MCF-7
cells (Po0.001) (Figure 9C).
We next found that BRCA1 (but not control) siRNA inhibited
basal ERSEwt and ERSE-II reporter activity (Po0.001)
(Figure 9D), whereas wtBRCA1 (but not empty pcDNA3 vector)
enhanced basal ERSEwt and ERSE-II signalling (Po0.001)
Figure 9E). Pretreatment with BRCA1-siRNA severely attenuated
the ability of I3C to upregulate ERSEwt and ERSE-II reporter
activity in T47D and MCF-7 cells (Po0.001) (Figure 9F). Finally,
pretreatment with BRCA1 (but not control) siRNA, blocked the
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Figure 7 Thapsigargin and tunicamycin upregulate BRCA gene expression. (A, B) Dose–response for induction of BRCA mRNAs by thapsigargin in
T47D (A) and MCF-7 (B) cells. Subconfluent proliferating cells were incubated with the indicated doses of thapsigargin for 24-h and then harvested for
semiquantitative RT–PCR analysis of BRCA1, BRCA2, and b-actin (control gene). (C) Time course for induction of BRCA1 mRNAs by thapsigargin in MCF-
7 cells. MCF-7 cells were incubated with thapsigargin (300nM) for different time intervals up to 48-h and then harvested for semiquantitative RT–PCR
analysis of BRCA1, BRCA2, and b-actin. (D, E) Dose–response for induction of BRCA1 protein by thapsigargin in T47D (D) and MCF-7 (E) cells. Cells
were incubated with the indicated doses of thapsigargin for 24-h and then harvested for Western blotting to detect BRCA1 and actin (control for loading
and transfer). (F, G) Dose–response for induction of BRCA proteins by tunicamycin in T47D (F) and MCF-7 (G) cells. Cells were incubated with the
indicated doses of thapsigargin for 24-h and then harvested for Western blotting to detect BRCA1, BRCA2, and actin.
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(Po0.001) (Figure 9G). These findings suggest that both I3C and
genistein stimulate ERSE activity and BRCA1 is required for I3C-
and genistein-induced ERSE activity.
DISCUSSION
We showed that two phytochemicals with potential cancer
prevention activity, I3C and genistein, each upregulate expression
of the BRCA1 and BRCA2 breast cancer genes. Significant
increases in BRCA1 and BRCA2 protein levels (42-fold) were
observed at relatively low doses of these agents (20mM of I3C and
0.5–1mM of genistein), suggesting potential physiologic relevance
of these findings. While I3C and genistein have a variety of cellular
actions in vitro and protect against various types of cancer in vivo,
it is unclear which of these actions is essential for cancer
prevention and to what degree. BRCA1 and BRCA2 have been
identified as tumour suppressors for several different hormone-
responsive cancer types (breast and prostate cancers (BRCA1 and
BRCA2) and endometrial and cervical cancer (BRCA1)) and a non-
endocrine cancer type (pancreas cancer (BRCA1 and BRCA2))
(Struewing et al, 1997; Thompson and Easton, 2002; Aretini et al,
2003; Edwards et al, 2003). Thus, it is plausible to hypothesise that
some of the chemoprevention activity of I3C and genistein is due
to stimulation of BRCA expression.
Evidence of a role for BRCA1 in sporadic mammary carcino-
genesis supports this idea. Thus, BRCA1 expression is decreased
or absent in a significant proportion of sporadic breast and
ovarian cancer cases, in part because of hypermethylation of the
BRCA1 promoter on CpG islands (Wilson et al, 1999; Rice et al,
2000). A significant fraction of sporadic breast cancers (46%) were
found to be haploinsufficient for BRCA1 (Staff et al, 2003).
Moreover, several agents that may contribute to breast cancer
development (polycyclic aromatic hydrocarbons (e.g., benzo(a)-
pyrene) and alcohol) downregulate BRCA1 expression (Fan et al,
2000; Jeffy et al, 2002). While the loss of BRCA1 expression or
function is linked to breast cancer, the role of upregulation of
either BRCA gene in preventing cancer is unclear. Several studies
suggest that BRCA expression is strongly induced in proliferating
cells undergoing differentiation, including those in the mammary
gland during puberty and pregnancy (Rajan et al, 1996, 1997;
Bernard-Gallon et al, 2001). These findings suggest that the BRCA
genes are highly induced and play anticarcinogenic roles at specific
times during mammary development. If so, then agents that
upregulate BRCA1 and BRCA2 in mammary epithelial cells may
prevent cancer development.
Genistein has multiple biologic actions, some of which may
contribute to its cancer prevention activity: (1) inhibition of
hormone-dependent and -independent cancer cell proliferation,
antiapoptotic signalling (NF-kB and c-Akt), toposomerase IIa
activity, tyrosine kinase activity, and angiogenesis; and (2)
stimulation of TGF-b signal transduction, p53 and Chk2 kinase
activity, antioxidant activity, and differentiation (Castle and
Thrasher, 2002; Sarkar and Li, 2002). Our findings indicate that
genistein upregulates BRCA1 and BRCA2 expression in breast and
prostate cancer cell lines. In a previous study, genistein caused an
increase in BRCA2 mRNA (but not protein) levels in MDA-MB-231
and MCF-10A but not in MCF-7 cells (Vissac-Sabatier et al, 2003).
In that study, daidzein, another soy isoflavone, had no effect on
BRCA2 expression. There were methodologic differences between
that study and ours (e.g., the use of affinity chromatography to
measure BRCA2 protein). Nonetheless, the reason for the
differences with our results are unclear, since we found that the
BRCA2 protein was highly induced in a reproducible fashion in
four different human cancer cell lines.
Several factors suggest that BRCA induction by phytochemicals
is not due to ER-a signalling: (1) the BRCA genes were induced
equally by I3C and genisein in MCF-7 cells treated without vs with
ICI182,780 (which causes degradation of ER-a); (2) another anti-
oestrogen, Tamoxifen, had no effect on BRCA1 levels (Jones et al,
2005); (3) BRCA1 and BRCA2 were strongly induced by I3C and
genistein in ER-a-negative DU-145 prostate cancer cells; and (4)
I3C upregulates BRCA1 expression in ER-a negative breast cancer
(MDA-MB-231 and MDA-MB-468) and cervical cancer cells or
human foreskin keratinocytes (Meng et al, 2000ab, 2001; Carter
et al, 2002). Finally, our results suggest induction of BRCA
expression by an oestrogen-independent mechanism involving an
endoplasmic reticulum stress-like response.
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Figure 8 Induction of BRCA expression by I3C requires the kinase PERK
(EIFAK3). (A) Dominant negative (DN) PERK blocks I3C induction of
BRCA protein. Subconfluent proliferating MCF-7 cells were transfected
overnight with control (vehicle only), empty pcDNA3 vector, or DN-PERK
(15-mg plasmid DNA per 100-mm dish) using Lipofectaminet. The
transfected cells were washed, allowed to recover for several hours,
treated7I3C for 24-h, and harvested for Western blotting to detect
BRCA1, BRCA2, or actin (control for loading and transfer). (B) Dominant
negative IRE1 fails to block I3C induction of BRCA protein. Assays were
performed as described in (A), except using DN-IRE1 instead of DN-PERK.
(C) Dominant negative ATF4 fails to block I3C induction of BRCA protein.
Assays were performed as described in (A), except using DN-ATF4
instead of DN-PERK.
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sWe showed some activities of I3C and genistein are blocked or
partially reversed by inhibition of BRCA1: (1) upregulation of
BRCA2 by I3C or genistein; (2) cytotoxicity due to high doses of
I3C; (3) inhibition of E2-stimulated ER-a activity by I3C and/or
genistein in breast cancer cells; and (4) inhibition of DHT-
stimulated AR activity by I3C and genistein in prostate cancer
cells. Studies using under- and overexpression of BRCA1 and
BRCA2 suggest that the ability of BRCA1 to modulate I3C
cytotoxicity is due, in part, to BRCA2. On the other hand, the
I3C inhibition of ER-a activity is due mostly to BRCA1, and not
BRCA2. Indole-3carbinol and genistein may exert BRCA1-depen-
dent and BRCA1-independent effects on ER-a and AR signalling,
since BRCA1-siRNA can influence ER-a and AR activity in the
absence of phytochemicals. It is also noteworthy that some of the
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seffects of genistein on oestrogen receptor signalling may be
mediated through ER-b, since genistein has a higher affinity for
ER-b than for ER-a (Kuiper et al, 1998).
Rescue of the inhibition of ER-a by I3C and/or genistein is
consistent with previous studies showing that wtBRCA1 inhibits
ER-a signalling and a DN-BRCA1 rescues the inhibition (Fan et al,
1999b; 2001a,b). However, the finding that BRCA1-siRNA
stimulates AR activity and partially reverses the inhibition of
DHT-induced AR activity by I3C and genistein is somewhat
surprising, since wtBRCA1 and wtBRCA2 were reported to
stimulate AR signalling (Yeh et al, 2000; Shin and Verma, 2003).
Presently, we do not have a good explanation for this discrepancy;
but we have observed that wtBRCA1 either has no effect on or
modestly enhances DHT-stimulated activation of several ARE-
driven reporters (ARE-TK-Luc and MMTV-Luc) (unpublished
results), suggesting that the consequences of underexpressing
BRCA1 may not be predictable based on overexpression models.
Interestingly, treatment of LNCaP cells with BRCA1-siRNA plus
DHT caused an increase in AR protein, which may have
contributed to the increase in DHT-stimulated AR activity in cells
treated with BRCA1-siRNA. The increase in AR protein was not
due to an increase in mRNA but was associated with a slight
decrease in electrophoretic mobility, consistent with post-transla-
tion modification (e.g., phosphorylation). Since the cofactor
environment is critical to AR activity, it is also possible that loss
of BRCA1 causes upregulation of an AR coactivator(s) and/or
downregulation of an AR corepressor(s).
In a recent study, it was reported that prepubertal exposure of
rats (age 7–20 days) to genistein caused prolonged upregulation of
BRCA1 mRNA expression in the mammary glands (Cabanes et al,
2004). The induction of BRCA1 was associated with morphologic
evidence of mammary differentiation and a reduced susceptibility
to 7,12-dimethylbenz[a]anthracene-induced mammary tumours.
These findings suggest that BRCA1 may contribute to protection
against mammary tumorigenesis by genistein, but cause and effect
have not yet been proven.
Taken together, our findings suggest that BRCA1 and BRCA2 are
potential molecular targets for the chemoprevention agents I3C
and genistein. Although we did not extensively study combinations
of agents, our findings suggest that I3C and genistein may act
synergistically or supra-additively to stimulate BRCA1 and BRCA2
expression. Further work is required to determine if BRCA1 and
BRCA2 are potential intermediate biomarkers that predict the
efficacy of these or other prevention agents and whether a
combination of I3C and genistein can provide greater cancer
prevention efficacy with the same or less toxicity (i.e., a better
therapeutic ratio).
Our studies suggest that I3C induces BRCA expression via an
endoplasmic reticulum stress-like pathway, although this hypo-
thesis needs to be definitively proved. A previous study revealed
that the I3C metabolite DIM activates multiple endoplasmic
reticulum stress pathways, leading to induction of downstream
target genes (e.g., chaperones) and activation of c-Jun N-terminal
kinases JNK1 and JNK2 (Sun et al, 2004). Here, we found that I3C
activates ERSE and ERSE-II signalling and induces CHOP
promoter activity in T47D and MCF-7 cells, consistent with an
endoplasmic reticulum stress-like response. Importantly, two
agents known to cause endoplasmic reticulum stress, thapsigargin
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Figure 9 Stimulation of endoplasmic reticulum stress signalling by I3C, genistein, and BRCA1. (A) Stimulation of ERSE-driven reporter activity by I3C and
tunicamycin. MCF-7 or T47D cells were transfected overnight with the indicated luciferase reporter, washed, postincubated with tunicamycin (1mg/ml) and/
or I3C (100mM) for 24-h, and harvested for luciferase assays. Luciferase activity was expressed relative to that observed using the ERSEwt-Luc reporter in the
absence of tunicamycin or I3C. Values are means7s.e.m.’s of four replicate wells. The reporters tested were driven by the wt endoplasmic reticulum stress-
response element (ERSEwt-Luc), a mutant ERSE (ERSEmut-Luc), and three copies of the ERSE-II element (ERSEII3x-Luc). (B) Stimulation of ERSE reporter
activity by genistein. Assays were performed as above, except that after transfection of reporters, the cells were treated with genistein (0.5 or 1.0mM) for
24h. (C) Stimulation of CHOP promoter–reporter activity by I3C and gensitein. Cells were transfected overnight with the a reporter composed of the
CHOP promoter upstream of a luciferase gene (pCHOP-Luc), washed, and postincubated with different doses of I3C or genistein for 24h. Luciferase
activity was expressed relative to that in the absence of I3C or genistein. The values are means7s.e.m.’s of four replicate wells. (D) Dependence of basal
ERSE reporter activity on endogenous BRCA1. Proliferating cells were pretreated with BRCA1-siRNA, control-siRNA (50nM 72-h), or no siRNA (vehicle
only). After 48h of siRNA treatment, they were transfected with the indicated ERSE reporter. After siRNA treatment and transfection, the cells were
washed, postincubated for 24h, and harvested for luciferase assays. Values are expressed relative to the ERSEwt-Luc control (no siRNA) and are
means7s.e.m.’s of four replicate wells. (E) Stimulation of ERSE reporter activity by wtBRCA1. Cells were cotransfected overnight with wtBRCA1, empty
pcDNA3 vector, or no vector (vehicle only) and the indicated reporter. The cells were washed and postincubated for 24h. Luciferase values are expressed
relative to the ERSEwt-Luc reporter in the absence of wtBRCA1 or pcDNA3 and are means7s.e.m.’ of quadruplicate wells. (F) Dependence of I3C-
stimulated ERSE activity on endogenous BRCA1. Assays were performed as described in (D), except that after siRNA treatment and transfection, the cells
were postincubated for 24h in the absence or presence of I3C (100mM). (G) Dependence of genistein-stimulated ERSE activity on endogenous BRCA1.
Assays were performed as described in (F), except using genistein (1mM) instead of I3C.
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sand tunicamycin, also induced BRCA1 and BRCA2 expression; and
a DN PERK, an upstream component of endoplasmic and
nutritional stress-response pathways, blocked I3C-induced BRCA1
expression.
The mechanism(s) by which endoplasmic reticulum signalling
induces BRCA1 expression remains to be determined. We analysed
the BRCA1 promoter sequence (GeneBank Accession U37574) for
canonical ERSE (ccaat-n9-ccacg), UPRE (tgacgtgg/a), and ERSE-II
(attgg-n-ccacg) elements (where n¼any nucleotide). The 1.5-kb
region upstream of the BRCA1-coding sequence did not contain
any complete ERSE or ERSE-II elements, but it did contain a
number of half-sites. However, this region does contain two
possible UPREs: tgacgtga and tggcgtgg. The role of these elements
in mediating phytochemical induction of BRCA1 remains to be
determined.
Our results also suggest a role for BRCA1 in endoplasmic
reticulum stress signalling, since BRCA1 was found to positively
regulate ERSE and ERSE-II activity. Thus, knockdown of BRCA1
inhibited basal ERSE and ERSE-II activity, while overexpression of
BRCA1 stimulated ERSE and ERSE-II activity; and knockdown of
BRCA1 reduced the I3C-induced ERSE and ERSE-II activity. These
results are consistent with a model in which BRCA1 is both a target
and a mediator of the endoplasmic reticulum stress response, as
are other transcriptional regulators, such as activating transcrip-
tion factor 6 (ATF6) and X box-binding protein 1 (XBP1). Finally,
we found that low doses of genistein (0.5–1.0mM) significantly
induced ERSE, ERSE-II, and CHOP promoter activity, suggesting
that genistein can activate endoplasmic reticulum stress response
signalling, although the extent of the pathway activated and its
significance remain to be determined. The ability of genistein to
induce endoplasmic reticulum stress response signalling could, in
part, explain how low doses of genistein induce BRCA gene
expression.
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